Mutant p53: A therapeutic target for the treatment of triple-negative breast cancer?
Naoise C. Synnott
No relevant relationships to disclose
Aisling Pierce
No relevant relationships to disclose
Maeve Mullooly
No relevant relationships to disclose
Francesco Caiazza
No relevant relationships to disclose
Patricia M. McGowan
No relevant relationships to disclose
Norma O'Donovan
No relevant relationships to disclose
John Crown
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Roche; Sanofi
Research Funding - GlaxoSmithKline; Novartis; Pfizer; Roche; Sanofi
Michael J. Duffy
No relevant relationships to disclose